The independent platform for news, articles and advice for professionals in laboratory medicine

Fujirebio expands neurodegenerative diseases assay menu

Fujirebio has announced the availability of the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE G immunoassay systems.

These chemiluminescent enzyme immunoassays allow for the quantitative measurement of neurofilament light (NfL) in human cerebrospinal fluid (CSF) and plasma/serum, respectively, within just 35 minutes. The two assays are available for research use only.

The new biomarker tests will allow researchers and clinical research professionals across the world to further study the clinical utility of NfL in diverse neurodegenerative disease conditions such as multiple sclerosis, Parkinson's or Alzheimer's disease

“In 2022, we introduced three fully automated blood-based assays for the detection of pTau181, β-Amyloid1-42 and β-Amyloid1-40, and we are now proud to once again expand our neurodegenerative disease portfolio with the highly anticipated NfL biomarker,” Christiaan De Wilde, CEO of Fujirebio Europe and Global Head Neuro Business. “The assay menu offered by other industry leaders today is still limited and we are working diligently to create a solid line up of tests for the entire neurodegenerative disease field as quickly as possible.”

The new biomarker tests will allow researchers and clinical research professionals across the world to further study the clinical utility of NfL in diverse disease conditions such as multiple sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s, or Alzheimer’s disease as well as in acute situations such as traumatic brain injury. NfL is considered a promising biomarker for disease activity, progression, prognosis, and monitoring effectiveness of therapies.

Laboratory professionals can select their preferred specimen matrix and measure NfL on the fully automated, random-access LUMIPULSE G platform. This standardised immunoassay system family is widely available and used in routine labs active in the field of neurological diseases with its current assay menu. The LUMIPULSE G platform meets the necessary throughput, quality, and regulatory requirements to support possible future routine use of NfL in addition to the existing portfolio.

 

Upcoming Events

UKMedLab23

Royal Armouries, Leeds
12-14 June 2023

Liverpool Pathology 2023

University of Liverpool
27-29 June

Microscience Microscopy Congress 2023 (mmc 2023, incorporating EMAG 2023)

Manchester Central Conference Centre
4-6 July 2023

Annual SHOT Symposium 2023

Etihad Stadium, Manchester, M11 3FF
4 July 2023

SHOT webinar: Positive patient identification for safe transfusions in adults

Online
11 July

SHOT webinar: Accurate and complete patient identification for safe transfusions in children

Online
19 July

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

UKMedLab23

Royal Armouries, Leeds
12-14 June 2023

Liverpool Pathology 2023

University of Liverpool
27-29 June

Microscience Microscopy Congress 2023 (mmc 2023, incorporating EMAG 2023)

Manchester Central Conference Centre
4-6 July 2023

Annual SHOT Symposium 2023

Etihad Stadium, Manchester, M11 3FF
4 July 2023

SHOT webinar: Positive patient identification for safe transfusions in adults

Online
11 July

SHOT webinar: Accurate and complete patient identification for safe transfusions in children

Online
19 July

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999 Fax: 01892 616177
www.step-communications.com
© 2023 Step Communications Ltd. Registered in England. Registration Number 3893025